Wai Lee, MD
Cardiovascular Disease · Elkhart, INNPI 1265435861
Payments from drug & device makers
Across 934 payments — averaging $475.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$141K
- Boehringer Ingelheim$57K
- Johnson & Johnson$51K
- AstraZeneca$35K
- Lilly USA, LLC$34K
- E.r. Squibb & Sons, L.L.C.$30K
- plus $97K from 30 others
What the payments were for
- Consulting fees$6,0602%
- Speaking & faculty fees$276,89386%
- Travel & lodging$22,6707%
- Food & beverage$14,8405%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 82 | $141,006 |
| Boehringer Ingelheim | 107 | $57,139 |
| Johnson & Johnson | 157 | $50,568 |
| AstraZeneca | 67 | $34,528 |
| Lilly USA, LLC | 29 | $33,856 |
| E.r. Squibb & Sons, L.L.C. | 108 | $30,275 |
| Lexicon Pharmaceuticals, Inc. | 52 | $25,005 |
| Bayer | 38 | $23,753 |
| Esperion Therapeutics, Inc. | 39 | $21,971 |
| Sanofi-aventis U.S. LLC | 18 | $9,051 |
| Amgen | 66 | $7,772 |
| Regeneron Healthcare Solutions, Inc. | 19 | $3,584 |
| Merck | 38 | $3,351 |
| Bristol Myers Squibb | 1 | $600 |
| Pfizer | 45 | $583 |
| Abbott | 9 | $320 |
| Actelion Pharmaceuticals US, Inc. | 15 | $244 |
| Amarin Pharma, Inc. | 7 | $105 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $83 |
| Gilead | 5 | $79 |
| Impulse Dynamics (USA) Inc. | 1 | $65 |
| Irhythm Technologies, Inc. | 2 | $62 |
| Scpharmaceuticals Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Chiesi USA, Inc. | 3 | $50 |
| Boston Scientific | 2 | $50 |
| Aegerion Pharmaceuticals, Inc. | 2 | $32 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| Novo Nordisk | 1 | $25 |
| United Therapeutics Corporation | 1 | $24 |
| Heartflow, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$444,425 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 787 | $723,456 |
| JardianceEmpagliflozin | 381 | $356,452 |
| EntrestoSacubitril/Valsartan | 282 | $286,528 |
| XareltoRivaroxaban | 241 | $259,519 |
| FarxigaDapagliflozin Propanediol | 200 | $168,758 |
| Repatha SureclickEvolocumab | 172 | $165,550 |
| MultaqDronedarone Hcl | 48 | $64,180 |
| VerquvoVericiguat | 55 | $43,616 |
| Praluent PenAlirocumab | 36 | $35,235 |
| NexlizetBempedoic Acid/Ezetimibe | 30 | $30,119 |
| Dofetilide | 118 | $21,254 |
| BrilintaTicagrelor | 30 | $19,164 |
| Propafenone Hcl | 181 | $11,521 |
| DapagliflozinDapagliflozin Propanediol | 21 | $9,731 |
| Midodrine Hcl | 48 | $7,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $583 | $723,456787 claims |
| Boehringer IngelheimJardiance | $57,139 | $356,452381 claims |
| NovartisEntresto | $141,006 | $286,528282 claims |
| Johnson & JohnsonXarelto | $50,568 | $259,519241 claims |
| AstraZenecaFarxiga, Brilinta | $34,528 | $187,922230 claims |
| Sanofi-aventis U.S. LLCMultaq | $9,051 | $64,18048 claims |
| MerckVerquvo | $3,351 | $43,61655 claims |
| Esperion Therapeutics, Inc.Nexlizet | $21,971 | $30,11930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Elkhart
- Vijay MehtaElkhart$925K
- Troy WeirickElkhart$374K
- Charles MathisElkhart$64K
- John McGintyRichmond$3.7M
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.